Innovent Biologics, Inc. (FRA:6IB)

Market Cap	17.10B +158.8%
Revenue (ttm)	1.36B +53.2%
Net Income	134.59M
EPS	0.08
Shares Out	n/a
PE Ratio	127.07
Forward PE	49.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	26
Open	9.75
Previous Close	9.60
Day's Range	9.75 - 9.80
52-Week Range	4.48 - 11.70
Beta	n/a
RSI	61.77
Earnings Date	Mar 26, 2026

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 6,190
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6IB

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY